Lysosomal storage diseases occur due to incomplete metabolic degradation of macromolecules by various hydrolytic enzymes in the lysosome. Despite structural differences, most of the lysosomal enzymes share many common features including a lysosomal targeting motif and phosphotransferase recognition sites. β-Glucuronidase (GUSB) is an important lysosomal enzyme involved in the degradation of glucuronate-containing glycosaminoglycan. The deficiency of GUSB causes mucopolysaccharidosis type VII (MPSVII), leading to lysosomal storage in the brain. GUSB is a well-studied protein for its expression, sequence, structure, and function. The purpose of this review is to summarize our current understanding of sequence, structure, function, and evolution of GUSB and its lysosomal enzyme targeting. Enzyme replacement therapy reported for this protein is also discussed.
Get full access to this article
View all access options for this article.
References
1.
von FiguraK. Structure-function relationship for lysosomal enzymes. Acta Paediatr Suppl, 2007; 96:5.
2.
von FiguraK, HasilikA. Lysosomal enzymes and their receptors. Annu Rev Biochem, 1986; 55:167–193.
LehmanTJ, MillerN, NorquistB, UnderhillL, KeutzerJ. Diagnosis of the mucopolysaccharidoses. Rheumatology (Oxford), 2011; 50,Suppl 5:v41–v48.
5.
OlsonLJ, PetersonFC, CastonguayA, BohnsackRN, KudoM, GotschallRR, CanfieldWM, VolkmanBF, DahmsNM. Structural basis for recognition of phosphodiester-containing lysosomal enzymes by the cation-independent mannose 6-phosphate receptor. Proc Natl Acad Sci USA, 2010; 107:12493–12498.
6.
RossCJ, BastedoL, MaierSA, SandsMS, ChangPL. Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells. Hum Gene Ther, 2000; 11:2117–2127.
7.
JainS, DrendelWB, ChenZW, MathewsFS, SlyWS, GrubbJH. Structure of human beta-glucuronidase reveals candidate lysosomal targeting and active-site motifs. Nat Struct Biol, 1996; 3:375–381.
8.
SlyWS. Prospects for enzyme replacement for lysosomal storage diseases. Birth Defects Orig Artic Ser, 1981; 17:201–213.
9.
SlyWS, VoglerC. Gene therapy for lysosomal storage disease: a no-brainer? Transplants of fibroblasts secreting high levels of beta-glucuronidase decrease lesions in the brains of mice with Sly syndrome, a lysosomal storage disease. Nat Med, 1997; 3:719–720.
10.
TomatsuS, MontanoAM, DungVC, GrubbJH, SlyWS. Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly Syndrome)Hum Mutat, 2009; 30:511–519.
11.
MillerRD, HoffmannJW, PowellPP, KyleJW, ShipleyJM, BachinskyDR, SlyWS. Cloning and characterization of the human beta-glucuronidase gene. Genomics, 1990; 7:280–283.
12.
OshimaA, KyleJW, MillerRD, HoffmannJW, PowellPP, GrubbJH, SlyWS, TropakM, GuiseKS, GravelRA. Cloning, sequencing, and expression of cDNA for human beta-glucuronidase. Proc Natl Acad Sci USA, 1987; 84:685–689.
13.
RayJ, BouvetA, DeSantoC, FyfeJC, XuD, WolfeJH, AguirreGD, PattersonDF, HaskinsME, HenthornPS. Cloning of the canine beta-glucuronidase cDNA, mutation identification in canine MPS VII, and retroviral vector-mediated correction of MPS VII cells. Genomics, 1998; 48:248–253.
14.
FyfeJC, KurzhalsRL, LassalineME, HenthornPS, AlurPR, WangP, WolfeJH, GigerU, HaskinsME, PattersonDF, SunH, JainS, YuhkiN. Molecular basis of feline beta-glucuronidase deficiency: An animal model of mucopolysaccharidosis VII. Genomics, 1999; 58:121–128.
15.
NishimuraY, RosenfeldMG, KreibichG, GublerU, SabatiniDD, AdesnikM, AndyR. Nucleotide sequence of rat preputial gland beta-glucuronidase cDNA and in vitro insertion of its encoded polypeptide into microsomal membranes. Proc Natl Acad Sci USA, 1986; 83:7292–7296.
16.
GallagherPM, D'AmoreMA, LundSD, GanschowRE. The complete nucleotide sequence of murine beta-glucuronidase mRNA and its deduced polypeptide. Genomics, 1988; 2:215–219.
17.
JeffersonRA, BurgessSM, HirshD. Beta-glucuronidase from Escherichia coli as a gene-fusion marker. Proc Natl Acad Sci USA, 1986; 83:8447–8451.
18.
ZhuJ, KangW, WolfeJH, FraserNW. Significantly increased expression of beta-glucuronidase in the central nervous system of mucopolysaccharidosis type VII mice from the latency-associated transcript promoter in a nonpathogenic herpes simplex virus type 1 vector. Mol Ther, 2000; 2:82–94.
19.
SperkerB, MurdterTE, SchickM, EckhardtK, BossletK, KroemerHK. Interindividual variability in expression and activity of human beta-glucuronidase in liver and kidney: Consequences for drug metabolism. J Pharmacol Exp Ther, 1997; 281:914–920.
20.
LeungJW, LiuYL, LeungPS, ChanRC, InciardiJF, ChengAF. Expression of bacterial beta-glucuronidase in human bile: An in vitro study. Gastrointest Endosc, 2001; 54:346–350.
KellerRK, TousterO. Physical and chemical properties of beta-glucuronidase from the preputial gland of the female rat. J Biol Chem, 1975; 250:4765–4769.
23.
IslamMR, GrubbJH, SlyWS. C-terminal processing of human beta-glucuronidase. The propeptide is required for full expression of catalytic activity, intracellular retention, and proper phosphorylation. J Biol Chem, 1993; 268:22627–22633.
24.
RosenfeldMG, KreibichG, PopovD, KatoK, SabatiniDD. Biosynthesis of lysosomal hydrolases: Their synthesis in bound polysomes and the role of co- and post-translational processing in determining their subcellular distribution. J Cell Biol, 1982; 93:135–143.
LiH, TakeuchiKH, ManlyK, ChapmanV, SwankRT. The propeptide of beta-glucuronidase. Further evidence of its involvement in compartmentalization of beta-glucuronidase and sequence similarity with portions of the reactive site region of the serpin superfamily. J Biol Chem, 1990; 265:14732–14735.
27.
FirekS, WhitelamGC, DraperJ. Endoplasmic reticulum targeting of active modified beta-glucuronidase (GUS) in transgenic tobacco plants. Transgenic Res, 1994; 3:326–331.
28.
TabasI, KornfeldS. Biosynthetic intermediates of beta-glucuronidase contain high mannose oligosaccharides with blocked phosphate residues. J Biol Chem, 1980; 255:6633–6639.
29.
KornfeldS. Trafficking of lysosomal enzymes in normal and disease states. J Clin Invest, 1986; 77:1–6.
30.
GrzeschikKH. Assignment of human genes: beta-glucuronidase to chromosome 7, adenylate kinase-1 to 9, a second enzyme with enolase activity to 12, and mitochondrial IDH to 15. Birth Defects Orig Artic Ser, 1976; 12:142–148.
31.
CatterallJF, LearySL. Detection of early changes in androgen-induced mouse renal beta-glucuronidase messenger ribonucleic acid using cloned complementary deoxyribonucleic acid. Biochemistry, 1983; 22:6049–6053.
32.
HieberVC. Cloning of a cDNA complementary to rat preputial gland beta-glucuronidase mRNA. Biochem Biophys Res Commun, 1982; 104:1271–1278.
33.
GuiseKS, KornelukRG, WayeJ, LamhonwahAM, QuanF, PalmerR, GanschowRE, SlyWS, GravelRA. Isolation and expression in Escherichia coli of a cDNA clone encoding human beta-glucuronidase. Gene, 1985; 34:105–110.
34.
PowellPP, KyleJW, MillerRD, PantanoJ, GrubbJH, SlyWS. Rat liver beta-glucuronidase. cDNA cloning, sequence comparisons and expression of a chimeric protein in COS cells. Biochem J, 1988; 250:547–555.
35.
ShipleyJM, MillerRD, WuBM, GrubbJH, ChristensenSG, KyleJW, SlyWS. Analysis of the 5′ flanking region of the human beta-glucuronidase gene. Genomics, 1991; 10:1009–1018.
36.
Kunert-KeilC, SperkerB, BienS, WolfG, GrubeM, KroemerHK. Involvement of AP-2 binding sites in regulation of human beta-glucuronidase. Naunyn Schmiedebergs Arch Pharmacol, 2004; 370:331–339.
37.
SperkerB, TomkiewiczC, BurkO, BaroukiR, KroemerHK. Regulation of human beta-glucuronidase by A23187 and thapsigargin in the hepatoma cell line HepG2. Mol Pharmacol, 2001; 59:177–182.
38.
CearleyCN, WolfeJH. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther, 2006; 13:528–537.
39.
GehrmannMC, OpperM, SedlacekHH, BossletK, CzechJ. Biochemical properties of recombinant human beta-glucuronidase synthesized in baby hamster kidney cells. Biochem J, 1994; 301, Pt 3:821–828.
40.
SinnottML. Ions, ion-pairs and catalysis by the lacZ beta-galactosidase of Escherichia coli. FEBS Lett, 1978; 94:1–9.
41.
GeblerJC, AebersoldR, WithersSG. Glu-537, not Glu-461, is the nucleophile in the active site of (lac Z) beta-galactosidase from Escherichia coli. J Biol Chem, 1992; 267:11126–11130.
42.
WallaceBD, WangH, LaneKT, ScottJE, OransJ, KooJS, VenkateshM, JobinC, YehLA, ManiS, RedinboMR. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science, 2010; 330:831–835.
43.
BonesJ, MittermayrS, McLoughlinN, HilliardM, WynneK, JohnsonGR, GrubbJH, SlyWS, RuddPM. Identification of N-glycans displaying mannose-6-phosphate and their site of attachment on therapeutic enzymes for lysosomal storage disorder treatment. Anal Chem, 2011; 83:5344–5352.
44.
WaheedA, HasilikA, CantzM, von FiguraK. Phosphorylation of lysosomal enzymes in fibroblasts. Marked deficiency of N-acetylglucosamine-1-phosphotransferase in fibroblasts of patients with mucolipidosis III. Hoppe Seylers Z Physiol Chem, 1982; 363:169–178.
45.
WaheedA, HasilikA, von FiguraK. UDP-N-acetylglucosamine:lysosomal enzyme precursor N-acetylglucosamine-1-phosphotransferase. Partial purification and characterization of the rat liver Golgi enzyme. J Biol Chem, 1982; 257:12322–12331.
46.
BaranskiTJ, FaustPL, KornfeldS. Generation of a lysosomal enzyme targeting signal in the secretory protein pepsinogen. Cell, 1990; 63:281–291.
47.
WaheedA, HasilikA, von FiguraK. Processing of the phosphorylated recognition marker in lysosomal enzymes. Characterization and partial purification of a microsomal alpha-N-acetylglucosaminyl phosphodiesterase. J Biol Chem, 1981; 256:5717–5721.
48.
ArighiCN, HartnellLM, AguilarRC, HaftCR, BonifacinoJS. Role of the mammalian retromer in sorting of the cation-independent mannose 6-phosphate receptor. J Cell Biol, 2004; 165:123–133.
49.
HasilikA, von FiguraK, ConzelmannE, NehrkornH, SandhoffK. Lysosomal enzyme precursors in human fibroblasts. Activation of cathepsin D precursor in vitro and activity of beta-hexosaminidase A precursor towards ganglioside GM2. Eur J Biochem, 1982; 125:317–321.
50.
HasilikA, WaheedA, CantzM, von FiguraK. Impaired phosphorylation of lysosomal enzymes in fibroblasts of patients with mucolipidosis III. Eur J Biochem, 1982; 122:119–123.
51.
Munier-LehmannH, MauxionF, HoflackB. Function of the two mannose 6-phosphate receptors in lysosomal enzyme transport. Biochem Soc Trans, 1996; 24:133–136.
BaranskiTJ, KoelschG, HartsuckJA, KornfeldS. Mapping and molecular modeling of a recognition domain for lysosomal enzyme targeting. J Biol Chem, 1991; 266:23365–23372.
56.
CuozzoJW, TaoK, CyglerM, MortJS, SahagianGG. Lysine-based structure responsible for selective mannose phosphorylation of cathepsin D and cathepsin L defines a common structural motif for lysosomal enzyme targeting. J Biol Chem, 1998; 273:21067–21076.
57.
CuozzoJW, TaoK, WuQL, YoungW, SahagianGG. Lysine-based structure in the proregion of procathepsin L is the recognition site for mannose phosphorylation. J Biol Chem, 1995; 270:15611–15619.
58.
SchoreyJ, ChirgwinJ. Mapping of lysosomal targeting determinants of cathepsin D. Adv Exp Med Biol, 1991; 306:339–342.
59.
NeufeldEF, LimTW, ShapiroLJ. Inherited disorders of lysosomal metabolism. Annu Rev Biochem, 1975; 44:357–376.
60.
ZhaoH, BrunkUT, GarnerB. Age-related lysosomal dysfunction: an unrecognized roadblock for cobalamin trafficking?Cell Mol Life Sci, 2011; 68:3963–3969.
61.
VoglerC, LevyB, GalvinN, LessardM, SoperB, BarkerJ. Early onset of lysosomal storage disease in a murine model of mucopolysaccharidosis type VII: undegraded substrate accumulates in many tissues in the fetus and very young MPS VII mouse. Pediatr Dev Pathol, 2005; 8:453–462.
62.
SlyWS, QuintonBA, McAlisterWH, RimoinDL. Beta glucuronidase deficiency: Report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. J Pediatr, 1973; 82:249–257.
63.
WuBM, TomatsuS, FukudaS, SukegawaK, OriiT, SlyWS. Overexpression rescues the mutant phenotype of L176F mutation causing beta-glucuronidase deficiency mucopolysaccharidosis in two Mennonite siblings. J Biol Chem, 1994; 269:23681–23688.
64.
MatteU, YogalingamG, BrooksD, LeistnerS, SchwartzI, LimaL, NoratoDY, BrumJM, BeesleyC, WinchesterB, GiuglianiR, HopwoodJJ. Identification and characterization of 13 new mutations in mucopolysaccharidosis type I patients. Mol Genet Metab, 2003; 78:37–43.
65.
VervoortR, IslamMR, SlyW, ChabasA, WeversR, de JongJ, LiebaersI, LissensW. A pseudodeficiency allele (D152N) of the human beta-glucuronidase gene. Am J Hum Genet, 1995; 57:798–804.
66.
YamadaS, TomatsuS, SlyWS, IslamR, WengerDA, FukudaS, SukegawaK, OriiT. Four novel mutations in mucopolysaccharidosis type VII including a unique base substitution in exon 10 of the beta-glucuronidase gene that creates a novel 5′-splice site. Hum Mol Genet, 1995; 4:651–655.
67.
IslamMR, TomatsuS, ShahGN, GrubbJH, JainS, SlyWS. Active site residues of human beta-glucuronidase. Evidence for Glu(540) as the nucleophile and Glu(451) as the acid-base residue. J Biol Chem, 1999; 274:23451–23455.
68.
VoglerC, SandsMS, GalvinN, LevyB, ThorpeC, BarkerJ, SlyWS. Murine mucopolysaccharidosis type VII: The impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease. J Inherit Metab Dis, 1998; 21:575–586.
69.
SandsMS, VoglerC, KyleJW, GrubbJH, LevyB, GalvinN, SlyWS, BirkenmeierEH. Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J Clin Invest, 1994; 93:2324–2331.
70.
VoglerC, LevyB, GalvinNJ, ThorpeC, SandsMS, BarkerJE, BatyJ, BirkenmeierEH, SlyWS. Enzyme replacement in murine mucopolysaccharidosis type VII: Neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy. Pediatr Res, 1999; 45:838–844.
71.
SandsMS, VoglerCA, OhlemillerKK, RobertsMS, GrubbJH, LevyB, SlyWS. Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII. J Biol Chem, 2001; 276:43160–434165.
72.
WolfeJH, SandsMS, BarkerJE, GwynnB, RoweLB, VoglerCA, BirkenmeierEH. Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer. Nature, 1992; 360:749–753.
73.
BossletK, CzechJ, LorenzP, SedlacekHH, SchuermannM, SeemannG. Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation. Br J Cancer, 1992; 65:234–238.
74.
MeltonRG, SherwoodRF. Antibody-enzyme conjugates for cancer therapy. J Natl Cancer Inst, 1996; 88:153–165.
75.
JollyR, MarshallN, MarshallJ, HartmanA, HemsleyK, WinnerL. Intracisternal enzyme replacement therapy in lysosomal storage diseases: Dispersal pathways, regional enzyme concentrations and the effect of post-treatment posture. Neuropathol Appl Neurobiol, 2012Dec1710.1111/nan.12010[Epub ahead of print]
DesnickRJ, SchuchmanEH. Enzyme replacement therapy for lysosomal diseases: Lessons from 20 years of experience and remaining challenges. Annu Rev Genomics Hum Genet, 2012; 13:307–335.
78.
LuJZ, BoadoRJ, HuiEK, ZhouQH, PardridgeWM. Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein. Biotechnol Bioeng, 2012; 108:1954–1964.
79.
GrubbJH, VoglerC, LevyB, GalvinN, TanY, SlyWS. Chemically modified beta-glucuronidase crosses blood-brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA, 2008; 105:2616–2621.
80.
HickmanS, ShapiroLJ, NeufeldEF. A recognition marker required for uptake of a lysosomal enzyme by cultured fibroblasts. Biochem Biophys Res Commun, 1974; 57:55–61.
81.
SlyWS. Gene therapy on the Sly. Nat Genet, 1993; 4:105–106.
82.
SandsMS, VoglerC, TorreyA, LevyB, GwynnB, GrubbJ, SlyWS, BirkenmeierEH. Murine mucopolysaccharidosis type VII: Long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation. J Clin Invest, 1997; 99:1596–1605.
83.
FreemanBJ, RobertsMS, VoglerCA, NicholesA, HoflingAA, SandsMS. Behavior and therapeutic efficacy of beta-glucuronidase-positive mononuclear phagocytes in a murine model of mucopolysaccharidosis type VII. Blood, 1999; 94:2142–2150.
84.
HuynhHT, GrubbJH, VoglerC, SlyWS. Biochemical evidence for superior correction of neuronal storage by chemically modified enzyme in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA, 2012; 109:17022–17027.
85.
VoglerC, SandsM, HigginsA, LevyB, GrubbJ, BirkenmeierEH, SlyWS. Enzyme replacement with recombinant beta-glucuronidase in the newborn mucopolysaccharidosis type VII mouse. Pediatr Res, 1993; 34:837–840.
86.
RowanDJ, TomatsuS, GrubbJH, MontanoAM, SlyWS. Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII. J Inherit Metab Dis, 2013; 36:235–246.
87.
YoungLS, SearlePF, OnionD, MautnerV. Viral gene therapy strategies: From basic science to clinical application. J Pathol, 2006; 208:299–318.
88.
EllinwoodNM, ViteCH, HaskinsME. Gene therapy for lysosomal storage diseases: The lessons and promise of animal models. J Gene Med, 2004; 6:481–506.
89.
MillerDG, WangPR, PetekLM, HirataRK, SandsMS, RussellDW. Gene targeting in vivo by adeno-associated virus vectors. Nat Biotechnol, 2006; 24:1022–1026.
90.
VoglerC, LevyB, GrubbJH, GalvinN, TanY, KakkisE, PavloffN, SlyWS. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA, 2005; 102:14777–14782.
91.
DonsanteA, LevyB, VoglerC, SandsMS. Clinical response to persistent, low-level beta-glucuronidase expression in the murine model of mucopolysaccharidosis type VII. J Inherit Metab Dis, 2007; 30:227–238.
92.
MaX, LiuY, TittigerM, HennigA, KovacsA, PopelkaS, WangB, HeratiR, BiggM, PonderKP. Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation. Mol Ther, 2007; 15:889–902.
93.
SaathoffM, BlumB, QuastT, KirfelG, HerzogV. Simultaneous cell death and desquamation of the embryonic diffusion barrier during epidermal development. Exp Cell Res, 2004; 299:415–426.
94.
DalyTM, OhlemillerKK, RobertsMS, VoglerCA, SandsMS. Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Ther, 2001; 8:1291–1298.
95.
McCownTJ, XiaoX, LiJ, BreeseGR, SamulskiRJ. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res, 1996; 713:99–107.
96.
KleinRL, MeyerEM, PeelAL, ZolotukhinS, MeyersC, MuzyczkaN, KingMA. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp Neurol, 1998; 150:183–194.
97.
OhashiT, WatabeK, UeharaK, SlyWS, VoglerC, EtoY. Adenovirus-mediated gene transfer and expression of human beta-glucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VII mice. Proc Natl Acad Sci USA, 1997; 94:1287–1292.
98.
WatsonGL, SaylesJN, ChenC, ElligerSS, ElligerCA, RajuNR, KurtzmanGJ, PodsakoffGM. Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus. Gene Ther, 1998; 5:1642–1649.
99.
SergueraC, SarkisC, RidetJL, ColinP, MoullierP, MalletJ. Primary adult human astrocytes as an ex vivo vehicle for beta-glucuronidase delivery in the brain. Mol Ther, 2001; 3:875–881.
100.
MontanoAM, OikawaH, TomatsuS, NishiokaT, VoglerC, GutierrezMA, OgumaT, TanY, GrubbJH, DungVC, OhashiA, MiyamotoK, OriiT, YonedaY, SlyWS. Acidic amino acid tag enhances response to enzyme replacement in mucopolysaccharidosis type VII mice. Mol Genet Metab, 2008; 94:178–189.
101.
SandsMS, WolfeJH, BirkenmeierEH, BarkerJE, VoglerC, SlyWS, OkuyamaT, FreemanB, NicholesA, MuzyczkaN, ChangPL, AxelrodHR. Gene therapy for murine mucopolysaccharidosis type VII. Neuromuscul Disord, 1997; 7:352–360.
102.
BrooksAI, SteinCS, HughesSM, HethJ, McCrayPMJr., SauterSL, JohnstonJC, Cory-SlechtaDA, FederoffHJ, DavidsonBL. Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc Natl Acad Sci USA, 2002; 99:6216–6221.
103.
SlyWS, VoglerC. Brain-directed gene therapy for lysosomal storage disease: going well beyond the blood- brain barrier. Proc Natl Acad Sci USA, 2002; 99:5760–5762.
104.
PaigenK. Mammalian beta-glucuronidase: Genetics, molecular biology, and cell biology. Prog Nucleic Acid Res Mol Biol, 1989; 37:155–205.
105.
ZhuBT, EvaristusEN, AntoniakSK, SarabiaSF, RicciMJ, LiehrJG. Metabolic deglucuronidation and demethylation of estrogen conjugates as a source of parent estrogens and catecholestrogen metabolites in Syrian hamster kidney, a target organ of estrogen-induced tumorigenesis. Toxicol Appl Pharmacol, 1996; 136:186–193.
106.
HazenbergMP, de HerderWW, VisserTJ. Hydrolysis of iodothyronine conjugates by intestinal bacteria. FEMS Microbiol Rev, 1988; 4:9–16.
107.
KreamerBL, SiegelFL, GourleyGR. A novel inhibitor of beta-glucuronidase: L-aspartic acid. Pediatr Res, 2001; 50:460–466.
108.
SperkerB, BackmanJT, KroemerHK. The role of beta-glucuronidase in drug disposition and drug targeting in humans. Clin Pharmacokinet, 1997; 33:18–31.
109.
BoelsterliUA, Ramirez-AlcantaraV. NSAID acyl glucuronides and enteropathy. Curr Drug Metab, 2011; 12:245–252.
WhitingJF, NarcisoJP, ChapmanV, RansilBJ, SwankRT, GollanJL. Deconjugation of bilirubin-IX alpha glucuronides: A physiologic role of hepatic microsomal beta-glucuronidase. J Biol Chem, 1993; 268:23197–23201.
114.
MakiT. Pathogenesis of calcium bilirubinate gallstone: Role of E. coli, beta-glucuronidase and coagulation by inorganic ions, polyelectrolytes and agitation. Ann Surg, 1966; 164:90–100.
115.
de GraafM, BovenE, ScheerenHW, HaismaHJ, PinedoHM. Beta-glucuronidase-mediated drug release. Curr Pharm Des, 2002; 8:1391–1403.
116.
SperkerB, WernerU, MurdterTE, TekkayaC, FritzP, WackeR, AdamU, GerkenM, DrewelowB, KroemerHK. Expression and function of beta-glucuronidase in pancreatic cancer: Potential role in drug targeting. Naunyn Schmiedebergs Arch Pharmacol, 2000; 362:110–115.
117.
LevvyGA. Baicalinase, a plant beta-glucuronidase. Biochem J, 1954; 58:462–469.
118.
BochardtA, HodalL, PalmgrenG, MattssonO, OkkelsFT. DNA methylation is involved in maintenance of an unusual expression pattern of an introduced gene. Plant Physiol, 1992; 99:409–414.
JeffersonRA, KavanaghTA, BevanMW. GUS fusions: Beta-glucuronidase as a sensitive and versatile gene fusion marker in higher plants. EMBO J, 1987; 6:3901–3907.
121.
PlatteeuwC, SimonsG, de VosWM. Use of the Escherichia coli beta-glucuronidase (gusA) gene as a reporter gene for analyzing promoters in lactic acid bacteria. Appl Environ Microbiol, 1994; 60:587–593.
122.
FarnleitnerAH, HockeL, BeiwlC, KavkaGG, MachRL. Hydrolysis of 4-methylumbelliferyl-beta-D-glucuronide in differing sample fractions of river waters and its implication for the detection of fecal pollution. Water Res, 2002; 36:975–981.
123.
SpencerB, WilliamsRT. Studies in detoxication. 35. Spectrophotometric determination of beta-glucuronidase using para-chlorophenylglucuronide as substrate. Biochem J, 1951; 48:537–546.
124.
Nimmo-SmithRH. p-Nitrophenyl-beta-glucuronide as substrate for beta-glucuronidase. Biochim Biophys Acta, 1961; 50:166–169.
125.
GlaserJH, ConradHE. Multiple kinetic forms of beta-glucuronidase. J Biol Chem, 1980; 255:1879–1894.
126.
GlaserJH, ConradHE. Chick embryo liver beta-glucuronidase. Comparison of activity on natural and artificial substrates. J Biol Chem, 1979; 254:6588–6597.
127.
MatsuuraT, HosodaK, IchihashiN, KazutaY, YomoT. Kinetic analysis of beta-galactosidase and beta-glucuronidase tetramerization coupled with protein translation. J Biol Chem, 2011; 286:22028–34.
128.
WongAW, HeS, GrubbJH, SlyWS, WithersSG. Identification of Glu-540 as the catalytic nucleophile of human beta-glucuronidase using electrospray mass spectrometry. J Biol Chem, 1998; 273:34057–34062.
129.
JacobsonRH, ZhangXJ, DuBoseRF, MatthewsBW. Three-dimensional structure of beta-galactosidase from E. coli. Nature, 1994; 369:761–766.
130.
MatsumuraI, EllingtonAD. In vitro evolution of beta-glucuronidase into a beta-galactosidase proceeds through non-specific intermediates. J Mol Biol, 2001; 305:331–339.
131.
GeddieML, MatsumuraI. Rapid evolution of beta-glucuronidase specificity by saturation mutagenesis of an active site loop. J Biol Chem, 2004; 279:26462–26468.
132.
SzklarczykD, FranceschiniA, KuhnM, SimonovicM, RothA, MinguezP, DoerksT, StarkM, MullerJ, BorkP, JensenLJ, von MeringC. The STRING database in 2011: Functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res, 2011; 39:D561–D568.
133.
IslamMR, WaheedA, ShahGN, TomatsuS, SlyWS. Human egasyn binds beta-glucuronidase but neither the esterase active site of egasyn nor the C terminus of beta-glucuronidase is involved in their interaction. Arch Biochem Biophys, 1999; 372:53–61.
134.
EisenhardtE, von DeimlingO. Interstrain variation of esterase-22, a new isozyme of the house mouse. Comp Biochem Physiol B, 1982; 73:719–724.
135.
Radominska-PandyaA, CzernikPJ, LittleJM, BattagliaE, MackenziePI. Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev, 1999; 31:817–899.
136.
BockKW, KohleC. Topological aspects of oligomeric UDP-glucuronosyltransferases in endoplasmic reticulum membranes: advances and open questions. Biochem Pharmacol, 2009; 77:1458–1465.
137.
FiguraN, MarriL, VerdianiS, CeccheriniC, BarberiA. Prevalence, species differentiation, and toxigenicity of Aeromonas strains in cases of childhood gastroenteritis and in controls. J Clin Microbiol, 1986; 23:595–599.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
